Candesartan (CV-11974) - Moligand™, 10mM in DMSO , Antagonist of AT 1 receptor, CAS No.139481-59-7, Antagonist of AT 1 receptor

CAS: 139481-59-7 Cat. No.: C408360 Molecular Weight: 440.45 EC Number: 604-138-8
AVAILABLE TO ORDER
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
C408360-1ml
2

$92.90

$134.90
Save $42.00 (31.13%)
Enter a quantity for the sizes you want to add.
🧪

Why this grade

Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 4 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Information

Candesartan (CV-11974) Candesartan (CV-11974) is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
In vitro

Candesartan binds with high specificity to the angiotensin II AT1 receptors in CHO-AT1 cells with K−1 of 0.001 min−1. Candesartan does not affect cell viability or proliferation but increases the expression of VEGF and interleukin-8 in the cultured medium of KU-19-19 cells. Candesartan (0.1 nM) could reduce the maximal contractile response to angiostensin II by approximately 50%.

In vivo

Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model Candesartan (0.5 mg/kg) decreases blood pressure and inhibits AT1 binding in the subfornical organ (SFO), paraventricular nucleus of the hypothalamus (PVN), nucleus of the solitary tract (NTS) and area postrema (AP) in WKY rats. Candesartan (0.3 mg/kg) pretreatment decreases the infarct area by 31% in adult spontaneously hypertensive rats, reduces the CBF decrease at the peripheral area of ischemia and the cortical volume of severe ischemic lesion.
Cell Data

cell lines:NCI-H2228 cells

Concentrations:10 μM

Incubation Time:48 hours

Powder Purity:≥99%

Specifications

Synonyms
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1, 1'-biphenyl]-4-yl]methyl]-
Specifications & Purity
Moligand™, 10mM in DMSO
Biochemical and Physiological Mechanisms
Candesartan (CV-11974) is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Grade
Moligand™
Action Type
ANTAGONIST
Mechanism of action
Antagonist of AT 1 receptor
Product Properties
ALogP4.1
Names and Identifiers
Isomeric SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
Alternate CAS 139481-59-7
NSC Number 759858
MeSH Entry Terms 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid;2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole;candesartan;CV 11974;CV-11974;CV11974
Molecular Weight 440.45
Reaxy-Rn 9232176
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9232176&ln=

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Associated Targets(Human)
AGTR1 Tclin Type-1 angiotensin II receptor (4 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
Freezing Point(°C)183-185°C
Documents & Articles
Citations of This Product
References
1. Yanan Guo, Shuang Cao, Bin Geng, Juanjuan Ma, Bo Yao.  (2024)  Determination of sacubitril and seven sartan drugs in serum samples by online solid phase extraction-liquid chromatography-tandem mass spectrometry.  JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,      [PMID:39603194] [10.1016/j.jpba.2024.116580]
2. Liang Song, Weiwei Zheng, Shuqin Wang, Zihe Zhai, Shifen Li, Jie Ding, Liyin Shen, Jinyue Zhang, Yang Zhu, Changyou Gao.  (2025)  ROS-responsive core–shell microgels for phase-specific treatment of myocardial infarction via programmed drug delivery.  CHEMICAL ENGINEERING JOURNAL,      [PMID:] [10.1016/j.cej.2025.160295]
3. Dafa Yi, Jiazong Ye, Zebei Lu, Leilei Lu, Tengfei Qi, Tong Luo, Xiuyun Peng, Abdullah Al Mamun, Quan Zhou, Daqing Chen, Shuanghu Wang.  (2025)  Effects of anti-hypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo.  DRUG METABOLISM AND DISPOSITION,      [PMID:40482432] [10.1016/j.dmd.2025.100094]
4. Zhenyu Wu, Xufang Huo, Yubing Huang, Taowu Gong, Pengcheng Zhao, Yuhang Zhu, Qingfan Zeng.  (2026)  AngII promotes hippocampal neuron ferroptosis via inhibiting the PPARγ/ACSL3 axis leading to hypertension-related cognitive impairment.  EXPERIMENTAL NEUROLOGY,      [PMID:] [10.1016/j.expneurol.2026.115755]
Solution Calculators
Reviews

Customer Reviews

Need help choosing the grade?

Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.

View Moligand™ grade guide →

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.